Published in J Virol on May 01, 2004
Ebola haemorrhagic fever. Lancet (2011) 8.28
Effective post-exposure treatment of Ebola infection. PLoS Pathog (2007) 3.69
Development of a new vaccine for the prevention of Lassa fever. PLoS Med (2005) 2.71
Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol (2008) 2.58
Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol (2009) 2.41
Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine (2008) 2.33
Wave-like spread of Ebola Zaire. PLoS Biol (2005) 2.23
Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog (2008) 2.10
A Recombinant Vesicular Stomatitis Virus Ebola Vaccine. N Engl J Med (2015) 2.08
A forward genetic strategy reveals destabilizing mutations in the Ebolavirus glycoprotein that alter its protease dependence during cell entry. J Virol (2010) 1.87
Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J Virol (2006) 1.85
Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS One (2009) 1.83
Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis (2011) 1.82
Ebola virus vaccines: an overview of current approaches. Expert Rev Vaccines (2014) 1.67
Ebola hemorrhagic Fever and the current state of vaccine development. Osong Public Health Res Perspect (2014) 1.67
Progress in filovirus vaccine development: evaluating the potential for clinical use. Expert Rev Vaccines (2011) 1.62
Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function. J Virol (2005) 1.61
An optofluidic nanoplasmonic biosensor for direct detection of live viruses from biological media. Nano Lett (2010) 1.57
Emerging targets and novel approaches to Ebola virus prophylaxis and treatment. BioDrugs (2013) 1.57
Nonsegmented negative-strand viruses as vaccine vectors. J Virol (2006) 1.53
Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection. PLoS Negl Trop Dis (2012) 1.51
Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. J Infect Dis (2011) 1.47
Postexposure treatment of Marburg virus infection. Emerg Infect Dis (2010) 1.43
Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl Trop Dis (2012) 1.32
Validation of assays to monitor immune responses in the Syrian golden hamster (Mesocricetus auratus). J Immunol Methods (2011) 1.31
Vesicular Stomatitis Virus-Based Vaccines for Prophylaxis and Treatment of Filovirus Infections. J Bioterror Biodef (2011) 1.28
Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus. J Virol (2011) 1.26
Replication-competent recombinant vesicular stomatitis virus encoding hepatitis C virus envelope proteins. J Virol (2007) 1.24
Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus. Sci Rep (2014) 1.24
Identification of cell surface molecules involved in dystroglycan-independent Lassa virus cell entry. J Virol (2011) 1.23
Vesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection. Virology (2007) 1.22
Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge. Virology (2008) 1.21
Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response. Vaccine (2010) 1.20
Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector. Springer Semin Immunopathol (2006) 1.12
Evaluation of Different Strategies for Post-Exposure Treatment of Ebola Virus Infection in Rodents. J Bioterror Biodef (2011) 1.09
Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates. J Virol (2013) 1.08
Mouse models for filovirus infections. Viruses (2012) 1.07
Clinical aspects of Marburg hemorrhagic fever. Future Virol (2011) 1.06
Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic. Virology (2010) 1.05
Mechanism of human antibody-mediated neutralization of Marburg virus. Cell (2015) 1.04
Use of the Syrian hamster as a new model of ebola virus disease and other viral hemorrhagic fevers. Viruses (2012) 1.04
Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus. J Infect Dis (2011) 1.03
Filovirus vaccines. Hum Vaccin (2011) 0.98
Uptake of rabies virus into epithelial cells by clathrin-mediated endocytosis depends upon actin. J Virol (2013) 0.98
Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection. Vaccine (2008) 0.97
Characterization of Lassa virus cell entry and neutralization with Lassa virus pseudoparticles. J Virol (2009) 0.97
Vesicular stomatitis virus as a vector to deliver virus-like particles of human norovirus: a new vaccine candidate against an important noncultivable virus. J Virol (2011) 0.96
Digital sensing and sizing of vesicular stomatitis virus pseudotypes in complex media: a model for Ebola and Marburg detection. ACS Nano (2014) 0.93
Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice. Vaccine (2011) 0.92
Advances in virus-like particle vaccines for filoviruses. J Infect Dis (2011) 0.92
Protective efficacy of a bivalent recombinant vesicular stomatitis virus vaccine in the Syrian hamster model of lethal Ebola virus infection. J Infect Dis (2011) 0.91
Inhibition of Lassa virus glycoprotein cleavage and multicycle replication by site 1 protease-adapted alpha(1)-antitrypsin variants. PLoS Negl Trop Dis (2009) 0.91
Development and Applications of VSV Vectors Based on Cell Tropism. Front Microbiol (2012) 0.90
Chinese hamster ovary cell lines selected for resistance to ebolavirus glycoprotein mediated infection are defective for NPC1 expression. Virology (2012) 0.90
Advanced vaccine candidates for Lassa fever. Viruses (2012) 0.90
Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates. PLoS One (2014) 0.88
Vaccination strategies against highly pathogenic arenaviruses: the next steps toward clinical trials. PLoS Pathog (2013) 0.87
Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses. Emerg Infect Dis (2015) 0.86
Single injection recombinant vesicular stomatitis virus vaccines protect ferrets against lethal Nipah virus disease. Virol J (2013) 0.86
Chimeric newcastle disease virus protects chickens against avian influenza in the presence of maternally derived NDV immunity. PLoS One (2013) 0.86
Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors. J Virol (2015) 0.84
The search for animal models for Lassa fever vaccine development. Expert Rev Vaccines (2013) 0.84
Serological assays based on recombinant viral proteins for the diagnosis of arenavirus hemorrhagic fevers. Viruses (2012) 0.84
Generation and characterization of a recombinant vesicular stomatitis virus expressing the glycoprotein of Borna disease virus. J Virol (2007) 0.84
Protective role of cytotoxic T lymphocytes in filovirus hemorrhagic fever. J Biomed Biotechnol (2011) 0.84
Characterization of Lassa virus glycoprotein oligomerization and influence of cholesterol on virus replication. J Virol (2009) 0.82
Arenavirus Genome Rearrangement for the Development of Live Attenuated Vaccines. J Virol (2015) 0.82
Ebola virus disease candidate vaccines under evaluation in clinical trials. Expert Rev Vaccines (2016) 0.82
Analysis of the expressed heavy chain variable-region genes of Macaca fascicularis and isolation of monoclonal antibodies specific for the Ebola virus' soluble glycoprotein. Immunogenetics (2005) 0.81
A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform. J Virol (2015) 0.81
Safety of recombinant VSV-Ebola virus vaccine vector in pigs. Emerg Infect Dis (2015) 0.79
Hunting Viral Receptors Using Haploid Cells. Annu Rev Virol (2015) 0.79
Ebola virus vaccines - reality or fiction? Expert Rev Vaccines (2016) 0.79
Stat1-Deficient Mice Are Not an Appropriate Model for Efficacy Testing of Recombinant Vesicular Stomatitis Virus-Based Filovirus Vaccines. J Infect Dis (2015) 0.78
Ebola vaccines in clinical trial: The promising candidates. Hum Vaccin Immunother (2016) 0.77
Construction of a Sonchus Yellow Net Virus minireplicon: a step toward reverse genetic analysis of plant negative-strand RNA viruses. J Virol (2013) 0.77
Chimeric Filoviruses for Identification and Characterization of Monoclonal Antibodies. J Virol (2016) 0.77
Pre-symptomatic diagnosis and treatment of filovirus diseases. Front Microbiol (2015) 0.77
Single-dose live-attenuated vesicular stomatitis virus-based vaccine protects African green monkeys from Nipah virus disease. Vaccine (2015) 0.76
Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge. PLoS One (2016) 0.75
Fighting Ebola: A Window for Vaccine Re-evaluation? PLoS Pathog (2017) 0.75
Enhancement of Ebola Virus Infection via Ficolin-1 Interaction with the Mucin Domain of GP Glycoprotein. J Virol (2016) 0.75
Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial. CMAJ (2017) 0.75
Prophylactic Efficacy of Quercetin 3-β-O-d-Glucoside against Ebola Virus Infection. Antimicrob Agents Chemother (2016) 0.75
Initiating a watch list for Ebola virus antibody escape mutations. PeerJ (2016) 0.75
Genomic profiling of host responses to Lassa virus: therapeutic potential from primate to man. Future Virol (2015) 0.75
Ebola Vaccine: How Far are we? J Clin Diagn Res (2017) 0.75
Ebola and Marburg virus vaccines. Virus Genes (2017) 0.75
Human immune system mouse models of Ebola virus infection. Curr Opin Virol (2017) 0.75
Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci U S A (1995) 9.08
Development of a preventive vaccine for Ebola virus infection in primates. Nature (2000) 8.32
The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc Natl Acad Sci U S A (1996) 7.02
A system for functional analysis of Ebola virus glycoprotein. Proc Natl Acad Sci U S A (1997) 6.86
Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature (2003) 6.35
Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. Science (1998) 5.83
GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases. Virology (1995) 5.34
An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell (2001) 4.79
A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis (1998) 4.50
Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc Natl Acad Sci U S A (1998) 4.33
Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins. Science (1998) 4.24
The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus. J Virol (1996) 3.89
Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proc Natl Acad Sci U S A (1996) 3.54
The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P. Proc Natl Acad Sci U S A (2001) 3.43
Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J Virol (1998) 3.07
Ebola virus: from discovery to vaccine. Nat Rev Immunol (2003) 2.72
Requirement for a non-specific glycoprotein cytoplasmic domain sequence to drive efficient budding of vesicular stomatitis virus. EMBO J (1998) 2.64
Mutational analysis of the putative fusion domain of Ebola virus glycoprotein. J Virol (1999) 2.41
Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis (2002) 2.26
Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies. J Virol (2001) 2.13
Processing of viral glycoproteins by the subtilisin-like endoprotease furin and its inhibition by specific peptidylchloroalkylketones. Biochimie (1994) 2.07
High-efficiency incorporation of functional influenza virus glycoproteins into recombinant vesicular stomatitis viruses. J Virol (1997) 2.07
The membrane-proximal stem region of vesicular stomatitis virus G protein confers efficient virus assembly. J Virol (2000) 1.96
Identification of Lassa virus glycoprotein signal peptide as a trans-acting maturation factor. EMBO Rep (2003) 1.85
Biosynthesis and role of filoviral glycoproteins. J Gen Virol (2001) 1.84
Vesicular stomatitis. Vet J (1999) 1.73
Characterization of membrane components of the erythrocyte involved in vesicular stomatitis virus attachment and fusion at acidic pH. J Gen Virol (1987) 1.73
Specific targeting to CD4+ cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins. J Virol (1997) 1.72
Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response. J Virol (2002) 1.69
Signal peptide of Lassa virus glycoprotein GP-C exhibits an unusual length. FEBS Lett (2003) 1.62
Transcript initiation and 5'-end modifications are separable events during vesicular stomatitis virus transcription. J Virol (1999) 1.61
Cell-mediated immunity to vesicular stomatitis virus infections in mice. Exp Cell Biol (1978) 1.57
Ecologic studies of vesicular stomatitis virus. I. Prevalence of infection among animals and humans living in an area of endemic VSV activity. Am J Epidemiol (1969) 1.52
Proteolytic processing of Marburg virus glycoprotein. Virology (2000) 1.43
Arenaviruses: protein structure and function. Curr Top Microbiol Immunol (2002) 1.38
Identification of two additional translation products from the matrix (M) gene that contribute to vesicular stomatitis virus cytopathology. J Virol (2002) 1.26
Contrasting effects of matrix protein on apoptosis in HeLa and BHK cells infected with vesicular stomatitis virus are due to inhibition of host gene expression. J Virol (2003) 1.22
Filovirus contamination of cell cultures. Dev Biol Stand (1992) 1.17
Vesicular stomatitis virus Indiana glycoprotein as a T-cell-dependent and -independent antigen. J Virol (1994) 1.14
Fewer protective cytotoxic T-cell epitopes than T-helper-cell epitopes on vesicular stomatitis virus. J Virol (1993) 1.09
Attenuation of recombinant vesicular stomatitis viruses encoding mutant glycoproteins demonstrate a critical role for maintaining a high pH threshold for membrane fusion in viral fitness. Virology (1998) 1.05
Presence of bovine viral diarrhea virus (BVDV) E2 glycoprotein in VSV recombinant particles and induction of neutralizing BVDV antibodies in mice. Virus Res (2000) 0.88
Caspase-3-like proteases are activated by infection but are not required for replication of vesicular stomatitis virus. Virus Res (2001) 0.85
Fas-mediated cytotoxicity induces degradation of vesicular stomatitis virus RNA transcripts and reduces viral titer. Mol Immunol (1997) 0.81
Genome-wide profiles of STAT1 DNA association using chromatin immunoprecipitation and massively parallel sequencing. Nat Methods (2007) 45.04
Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med (2003) 27.97
Genome sequence of the Brown Norway rat yields insights into mammalian evolution. Nature (2004) 24.40
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature (2009) 18.08
The Genome sequence of the SARS-associated coronavirus. Science (2003) 16.68
The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature (2012) 11.91
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet (2010) 10.97
Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature (2007) 10.40
Profiling the HeLa S3 transcriptome using randomly primed cDNA and massively parallel short-read sequencing. Biotechniques (2008) 10.02
Human and avian influenza viruses target different cell types in cultures of human airway epithelium. Proc Natl Acad Sci U S A (2004) 7.18
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med (2005) 6.77
Next-generation tag sequencing for cancer gene expression profiling. Genome Res (2009) 6.50
Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus. Nature (2004) 6.11
Persistence of Ebola Virus in Ocular Fluid during Convalescence. N Engl J Med (2015) 5.92
Dynamic remodeling of individual nucleosomes across a eukaryotic genome in response to transcriptional perturbation. PLoS Biol (2008) 5.88
Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med (2014) 5.74
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med (2009) 5.63
Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J Virol (2003) 5.11
Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Rev Med Virol (2002) 5.09
A physical map of the mouse genome. Nature (2002) 4.97
The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol (2003) 4.73
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell (2012) 4.41
ATR-X syndrome protein targets tandem repeats and influences allele-specific expression in a size-dependent manner. Cell (2010) 4.34
Global analysis of in vivo Foxa2-binding sites in mouse adult liver using massively parallel sequencing. Nucleic Acids Res (2008) 4.08
Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola. J Virol (2006) 4.01
New low-viscosity overlay medium for viral plaque assays. Virol J (2006) 3.92
Transcriptome analysis of the normal human mammary cell commitment and differentiation process. Cell Stem Cell (2008) 3.87
Effective post-exposure treatment of Ebola infection. PLoS Pathog (2007) 3.69
Panmicrobial oligonucleotide array for diagnosis of infectious diseases. Emerg Infect Dis (2007) 3.51
Person-to-person transmission of Nipah virus in a Bangladeshi community. Emerg Infect Dis (2007) 3.47
Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol (2004) 3.43
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med (2008) 3.42
Interaction of polymerase subunit PB2 and NP with importin alpha1 is a determinant of host range of influenza A virus. PLoS Pathog (2008) 3.37
Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet (2006) 3.15
DNA methylation and SETDB1/H3K9me3 regulate predominantly distinct sets of genes, retroelements, and chimeric transcripts in mESCs. Cell Stem Cell (2011) 3.10
HDAC3 is a critical negative regulator of long-term memory formation. J Neurosci (2011) 3.06
Novel avian influenza H7N3 strain outbreak, British Columbia. Emerg Infect Dis (2004) 2.90
Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium. J Virol (2006) 2.80
Ebola virus: from discovery to vaccine. Nat Rev Immunol (2003) 2.72
Molecular Evidence of Sexual Transmission of Ebola Virus. N Engl J Med (2015) 2.71
Development of a new vaccine for the prevention of Lassa fever. PLoS Med (2005) 2.71
Evaluation of perceived threat differences posed by filovirus variants. Biosecur Bioterror (2011) 2.62
Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture. J Virol (2002) 2.58
Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol (2008) 2.58
Pneumonia from human coronavirus in a macaque model. N Engl J Med (2013) 2.47
Lethal influenza virus infection in macaques is associated with early dysregulation of inflammatory related genes. PLoS Pathog (2009) 2.44
Molecular determinants of Ebola virus virulence in mice. PLoS Pathog (2006) 2.44
Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol (2009) 2.41
Altered receptor specificity and cell tropism of D222G hemagglutinin mutants isolated from fatal cases of pandemic A(H1N1) 2009 influenza virus. J Virol (2010) 2.38
Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry. J Virol (2004) 2.34
Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine (2008) 2.33
SARS--beginning to understand a new virus. Nat Rev Microbiol (2003) 2.30
Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc Natl Acad Sci U S A (2013) 2.29
Tyro3 family-mediated cell entry of Ebola and Marburg viruses. J Virol (2006) 2.24
Pause on avian flu transmission research. Science (2012) 2.24
The completion of the Mammalian Gene Collection (MGC). Genome Res (2009) 2.21
Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. PLoS Pathog (2010) 2.18
Global suppression of the host antiviral response by Ebola- and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence. J Virol (2006) 2.14
Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog (2008) 2.10
Production of novel ebola virus-like particles from cDNAs: an alternative to ebola virus generation by reverse genetics. J Virol (2004) 2.09
The ecology of Ebola virus. Trends Microbiol (2007) 2.08
Disease modeling for Ebola and Marburg viruses. Dis Model Mech (2009) 2.07
A BAC clone fingerprinting approach to the detection of human genome rearrangements. Genome Biol (2007) 2.03
A set of BAC clones spanning the human genome. Nucleic Acids Res (2004) 2.00
Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med (2013) 1.98
Ebola virus VP40 late domains are not essential for viral replication in cell culture. J Virol (2005) 1.97
DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus. J Virol (2004) 1.92
Ebola virus: unravelling pathogenesis to combat a deadly disease. Trends Mol Med (2006) 1.92
DNA synthesis and biological security. Nat Biotechnol (2007) 1.91
The Middle East respiratory syndrome coronavirus (MERS-CoV) does not replicate in Syrian hamsters. PLoS One (2013) 1.88
Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype. Proc Natl Acad Sci U S A (2007) 1.88
Identification of Lassa virus glycoprotein signal peptide as a trans-acting maturation factor. EMBO Rep (2003) 1.85
Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J Virol (2006) 1.85
Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood (2013) 1.84
Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS One (2009) 1.83
Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates. Sci Transl Med (2012) 1.83
Comet 81P/Wild 2 under a microscope. Science (2006) 1.83
Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis (2011) 1.82
Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci U S A (2013) 1.81
Identification of protective epitopes on ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses. J Virol (2003) 1.78
Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery. PLoS Pathog (2009) 1.78
Prospects for immunisation against Marburg and Ebola viruses. Rev Med Virol (2010) 1.77
Inhibition of filovirus replication by the zinc finger antiviral protein. J Virol (2006) 1.76
Host response dynamics following lethal infection of rhesus macaques with Zaire ebolavirus. J Infect Dis (2011) 1.75
Ectodomain shedding of the glycoprotein GP of Ebola virus. EMBO J (2004) 1.73